SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q4 2025 (← Previous)

Filing Date: Feb 12, 2026

Total Value ($000): $706,377 (100.0% shares, 0.0% debt)

Holdings (13)

New Positions (1)

RARE Ultragenyx Pharmaceutical Inc. 0.4%

Value ($000) $3,168 Shares 137,753 Est. Cost $32.88 Unrealized 0.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
RARE	Ultragenyx Pharmaceutical Inc.	137,753	$3,168	0.4%	$32.88	0.0%	Common Stock	90400D108

Increased Positions (2)

ZBIO Zenas BioPharma, Inc 25.9%

Value ($000) $182,924 (+67.8%) Shares 5,037,854 (+2.6%) Est. Cost $18.35 Unrealized +79.2%

OCS Oculis Holding AG 1.8%

Value ($000) $12,801 (+125.8%) Shares 641,022 (+98.8%) Est. Cost $20.25 Unrealized -1.2%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ZBIO	Zenas BioPharma, Inc	5,037,854 (+2.6%)	$182,924 (+67.8%)	25.9%	$18.35	+79.2%	Common Stock	98937L105
OCS	Oculis Holding AG	641,022 (+98.8%)	$12,801 (+125.8%)	1.8%	$20.25	-1.2%	Ordinary Shares	H5870P102

Decreased Positions (1)

MLYS Mineralys Therapeutics Inc. 8.0%

Value ($000) $56,756 (-29.2%) Shares 1,563,966 (-26.0%) Est. Cost $14.62 Unrealized +174.3%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MLYS	Mineralys Therapeutics Inc.	1,563,966 (-26.0%)	$56,756 (-29.2%)	8.0%	$14.62	+174.3%	Common Stock	603170101

Unchanged Positions (9)

ACLX Arcellx, Inc. 21.7%

Value ($000) $153,000 Shares 2,346,630 Est. Cost $16.72 Unrealized +377.1%

CRSP CRISPR Therapeutics AG 15.1%

Value ($000) $106,913 Shares 2,038,763 Est. Cost $64.71 Unrealized -7.4%

ORIC ORIC Pharmaceuticals, Inc. 5.3%

Value ($000) $37,754 Shares 4,514,929 Est. Cost $6.71 Unrealized +71.5%

DSGN Design Therapeutics, Inc. 8.7%

Value ($000) $61,218 Shares 6,526,476 Est. Cost $16.67 Unrealized -53.0%

ALMS Alumis Inc. 2.7%

Value ($000) $19,129 Shares 1,959,896 Est. Cost $13.30 Unrealized -47.5%

SPRY ARS Pharmaceuticals, Inc. 6.6%

Value ($000) $46,750 Shares 4,012,903 Est. Cost $6.79 Unrealized +43.3%

ORKA Oruka Therapeutics, Inc 1.8%

Value ($000) $13,043 Shares 430,330 Est. Cost $33.46 Unrealized -16.7%

ENGN enGene Holdings Inc. 1.0%

Value ($000) $6,752 Shares 747,750 Est. Cost $11.04 Unrealized -27.4%

NKTX Nkarta, Inc. 0.9%

Value ($000) $6,167 Shares 3,333,333 Est. Cost $11.49 Unrealized -82.6%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	Arcellx, Inc.	2,346,630	$153,000	21.7%	$16.72	+377.1%	Common Stock	03940C100
CRSP	CRISPR Therapeutics AG	2,038,763	$106,913	15.1%	$64.71	-7.4%	Common Shares	H17182108
ORIC	ORIC Pharmaceuticals, Inc.	4,514,929	$37,754	5.3%	$6.71	+71.5%	Common Stock	68622P109
DSGN	Design Therapeutics, Inc.	6,526,476	$61,218	8.7%	$16.67	-53.0%	Common Stock	25056L103
ALMS	Alumis Inc.	1,959,896	$19,129	2.7%	$13.30	-47.5%	Common Stock	022307102
SPRY	ARS Pharmaceuticals, Inc.	4,012,903	$46,750	6.6%	$6.79	+43.3%	Common Stock	82835W108
ORKA	Oruka Therapeutics, Inc	430,330	$13,043	1.8%	$33.46	-16.7%	Common Stock	687604108
ENGN	enGene Holdings Inc.	747,750	$6,752	1.0%	$11.04	-27.4%	Common Shares	29286M105
NKTX	Nkarta, Inc.	3,333,333	$6,167	0.9%	$11.49	-82.6%	Common Stock	65487U108